Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | BAD | Q92934 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8773445 | 0.86 | HTR1A (0.50) | HTR1ACYP2D6SLC6A4MAP3K14KIF11 | |
| SCHEMBL27798379 | 0.80 | HTR1A (0.37) | HTR1ACYP2D6SLC6A4KIF11KDM4E | |
| SCHEMBL3167852 | 0.79 | CTSD (0.45) | HTR1ACYP2D6SLC6A4MAP3K14BACE1 | |
| SCHEMBL3177710 | 0.79 | CTSD (0.45) | HTR1ACYP2D6SLC6A4MAP3K14BACE1 | |
| SCHEMBL28795077 | 0.79 | KIF11 (0.46) | HTR1ACYP2D6SLC6A4KIF11ALDH1A1 | |
| SCHEMBL4366274 | 0.75 | MAP3K14 (0.53) | HTR1ACYP2D6SLC6A4MAP3K14KDM4E | |
| SCHEMBL24215112 | 0.75 | DAO (0.47) | HTR1ACYP2D6SLC6A4MAP3K14 | |
| SCHEMBL3777135 | 0.74 | TAAR1 (0.52) | CYP2D6ALDH1A1GAA | |
| SCHEMBL1271967 | 0.73 | MAP3K14 (0.51) | HTR1ACYP2D6SLC6A4MAP3K14GAA | |
| SCHEMBL24393413 | 0.73 | MAP3K14 (0.75) | HTR1ACYP2D6SLC6A4MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778970-B2 | Benzyl piperidine compound | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8778970-B2 | Benzyl piperidine compound | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-07-15 | — | — | US | disclosed |
| EP-2463286-A1 | BENZYL PIPERIDINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120130077-A1 | BENZYL PIPERIDINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120130077-A1 | BENZYL PIPERIDINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| WO-2011016468-A1 | BENZYL PIPERIDINE COMPOUND | 大日本住友製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130077-A1 | BENZYL PIPERIDINE COMPOUND | HTR1D, HTR1A, HTR1B | HTR1A 2/4885CYP2D6 620/4885SLC6A4 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.